Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel
NASDAQ:SPRB

Spruce Biosciences Q4 2025 Earnings Report

Spruce Biosciences logo
$58.09 -1.25 (-2.11%)
As of 01:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Spruce Biosciences EPS Results

Actual EPS
-$9.58
Consensus EPS
-$9.16
Beat/Miss
Missed by -$0.42
One Year Ago EPS
N/A

Spruce Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spruce Biosciences Announcement Details

Quarter
Q4 2025
Date
3/12/2026
Time
Before Market Opens
Conference Call Date
Monday, March 9, 2026
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Spruce Biosciences' Q4 2025 Press ReleasePress Release
(8-K)
Spruce Biosciences' Q4 2025 Annual reportAnnual report
(10-K)

Spruce Biosciences Earnings Headlines

Spruce Biosciences (SPRB) Expected to Announce Earnings on Tuesday
May 3 at 3:50 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30755000
Craig-Hallum initiates coverage of Spruce Biosciences (SPRB) with buy recommendation
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/craig-hallum-initiates-coverage-of-spruce-biosciences-sprb-with-buy-recommendation/ar-AA21SuLE
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 6 at 1:00 AM  |  American Alternative (Ad)
Why is Spruce Biosciences stock sinking Tuesday?
April 21, 2026  |  msn.comhttps://www.msn.com/en-us/money/markets/why-is-spruce-biosciences-stock-sinking-tuesday/ar-AA21nZlH
Spruce Biosciences prices $60M public offering at $50.00 per share
April 21, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/spruce-biosciences-prices-60m-public-offering-at-5000-per-share/ar-AA21mv0i
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
April 20, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260420707326/en/spruce-biosciences-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants/
See More Spruce Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spruce Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spruce Biosciences and other key companies, straight to your email.

About Spruce Biosciences

Spruce Biosciences (NASDAQ:SPRB) is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels. In parallel, Spruce is developing nevanimibe, an adrenocortical hormone synthesis inhibitor, to further address the hormonal imbalances associated with CAH. Both candidates have demonstrated promising safety and efficacy profiles in early-phase studies.

Since its founding in 2017, Spruce Biosciences has established a global clinical infrastructure with trial sites across North America and Europe, enabling the company to enroll patients in its pivotal studies efficiently. The company collaborates with academic centers and patient advocacy groups to support trial design and patient recruitment, underscoring its commitment to advancing care for individuals living with rare endocrine disorders.

Under the leadership of President and Chief Executive Officer Jonathan Porges, Spruce combines experienced management with a scientific advisory board comprised of experts in endocrinology and drug development. The company’s deliberate strategy of targeting well-defined patient populations aims to streamline regulatory pathways and bring transformative therapies to market for communities with few existing treatment options.

View Spruce Biosciences Profile
Earnings Tools